 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | DS-1055 / Daiichi Sankyo
Trial primary completion date, Metastases: A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Mar 8, 2023
P1, N=40, Recruiting, Sponsor: Daiichi Sankyo Co., Ltd.
Trial primary completion date: Mar 2023 --> Dec 2024
- | DS-1055 / Daiichi Sankyo
Trial completion date, Metastases: A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 10, 2023
P1, N=40, Recruiting, Sponsor: Daiichi Sankyo Co., Ltd.
Trial primary completion date: Mar 2023 --> Dec 2024 Trial completion date: Mar 2023 --> Dec 2024
- || DS-1055a / Daiichi Sankyo
Clinical: SVB cites one other anti-GARP in clinical development, $DSNKY's DS-1055a (Twitter) - Aug 1, 2022
- | DS-1055a / Daiichi Sankyo
Journal: Novel anti-GARP antibody DS-1055a augments antitumor immunity by depleting highly suppressive GARP + regulatory T cells. (Pubmed Central) - Feb 4, 2022
Moreover, DS-1055a decreased FoxP3 +CD4 + T cells in the TME and exhibited remarkable antitumor activity in a humanized mouse bearing HT29 tumor. We propose that DS-1055a is a new Treg-cell-targeted cancer immunotherapy agent with augmentation of antitumor immunity.
- ||||| DS-1055a / Daiichi Sankyo
Preclinical: anti-GARP antibody DS-1055a augments antitumor immunity by depleting Tregs in the TME. It was optimized for ADCC via afucosylation, targeting human not mouse GARP. Also showed Tregs in human TME have high GARP, CD25, OX40, GITR, CCR8, CTLA4, TIGIT, ICOS https://t.co/BMHTWXDSNI (Twitter) - Jun 8, 2021
- || DS-1055a / Daiichi Sankyo
uh-huh 1847 - Anti-GARP antibody DS-1055a augments antitumor immunity by depleting highly suppressive GARP+ regulatory T cells #AACR21 (Twitter) - Apr 7, 2021
- DS-1055a / Daiichi Sankyo
[VIRTUAL] Anti-GARP antibody DS-1055a augments antitumor immunity by depleting highly suppressive GARP+ regulatory T cells () - Mar 11, 2021 - Abstract #AACR2021AACR_3296;
P1
From these results, we propose that DS-1055a can be a new Treg cell-targeted regent that augments antitumor T cell immunity by depleting GARP+ Treg cells. Currently, a Phase I study of DS-1055a is on-going (NCT04419532).
- | DS-1055a / Daiichi Sankyo
Journal: Use of Autochthonous Lactiplantibacillus plantarum Strains to Produce Fermented Fish Products. (Pubmed Central) - Dec 22, 2020
plantarum 11, L. plantarum 69, and L. plantarum DSM1055) at 10 cfu/g and incubated at 10, 20, or 30°C for 7 days...In the second step, salami-like were produced according to the individuated formulation and inoculated with the studied starters (10 cfu/g); the fish mixture was stuffed into a natural casing and left to ferment at 30°C for 7 days. The use of the selected strains not only assured a correct fermentation but reduced the process time at only 2 days; during refrigerated storage, a good microbiological, chemico-physical and sensorial quality of the final product was recorded for at least 21 days.
- || DS-1055 / Daiichi Sankyo
Enrollment open, Metastases: A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 19, 2020
P1, N=40, Recruiting, Sponsor: Daiichi Sankyo Co., Ltd.
The use of the selected strains not only assured a correct fermentation but reduced the process time at only 2 days; during refrigerated storage, a good microbiological, chemico-physical and sensorial quality of the final product was recorded for at least 21 days. Not yet recruiting --> Recruiting
- || DS-1055 / Daiichi Sankyo
New P1 trial, Metastases: A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Jun 4, 2020
P1, N=40, Not yet recruiting, Sponsor: Daiichi Sankyo Co., Ltd.